The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cited by
Sorted by citations
Items 401–500 of 944
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Williams, S. T., Wells, G., Conroy, S., Gagg, H., Allen, R. J., Rominiyi, O., Helleday, T., Hullock, K., Pennington, C. E. W., Rantala, J., et al. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.32 · Cited by 35
The landscape of d16HER2 splice variant expression across HER2-positive cancers
Volpi, C. C., Pietrantonio, F., Gloghini, A., Fucà, G., Giordano, S., Corso, S., Pruneri, G., Antista, M., Cremolini, C., Fasano, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40310-5 · Cited by 32
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 33
Hu, S., Dai, H., Li, T. X., Tang, Y., Fu, W., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.022 · Cited by 31
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer
Bianchi, A. S., Lonardi, S., Aglietta, M., Martino, C., Ciardiello, F., Marsoni, S., & Siena, S. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0571 · Cited by 31
Self-citationAngelis, M. L. D., Francescangeli, F., Nicolazzo, C., Xhelili, E., Torre, F. L., Colace, L., Bruselles, A., Macchia, D., Vitale, S., Gazzaniga, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869485 · Cited by 31
Peng, K., Liu, R., Yu, Y., Liang, L., Yu, S., Xu, X., & Liu, T. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.031 · Cited by 31
A novel immunodeficient rat model supports human lung cancer xenografts
He, D., Zhang, J., Wu, W., Yi, N., He, W., Lü, P., Li, B., Yang, N., Wang, D., Xue, Z., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201800102rr · Cited by 31
Azaro, A., Rodon, J. A., Calles, A., Braña, I., Hidalgo, M. M., Lopez-Casas, P. P., Muñoz, M., Westwood, P., Miller, J. A., Moser, B. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0241-7 · Cited by 35
ERBB2 Emerges as a New Target for Colorectal Cancer
Pectasides, E., & Bass, A. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0730 · Cited by 30
Battaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 30
Cybulska, P., Stewart, J. M., Sayad, A., Virtanen, C., Shaw, P. A., Clarke, B. A., Stickle, N. H., Bernardini, M. Q., & Neel, B. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.01.019 · Cited by 30
Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer
Tan, E. S., Knepper, T. C., Wang, X., Permuth, J. B., Wang, L., Fleming, J. B., & Xie, H. (2022) · Cancers · doi:10.3390/cancers14092223 · Cited by 28
Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease
Bousquet, G., & Janin, A. (2016) · Pathobiology · doi:10.1159/000444533 · Cited by 35
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 30
Ahluwalia, P. K., Ballur, K., Leeman, T., Vashisht, A., Singh, H., Omar, N., Mondal, A. K., Vaibhav, K., Baban, B., & Kolhe, R. B. (2024) · Cancers · doi:10.3390/cancers16030480 · Cited by 31
Mouse tumour models to guide drug development and identify resistance mechanisms
Thakur, M. D., Pryer, N., & Singh, M. (2013) · The Journal of Pathology · doi:10.1002/path.4285 · Cited by 30
EGFR signaling in colorectal cancer: a clinical perspective
Frattini, M., Saletti, P., Molinari, F., & Dosso, S. D. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49002 · Cited by 32
Shologu, N., Szegezdi, É., Lowery, A., Kerin, M. J., Pandit, A. S., & Zeugolis, D. I. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.001 · Cited by 32
Ohkuma, R., Yada, E., Ishikawa, S., Komura, D., Ishizaki, H., Tamada, K., Kubota, Y., Hamada, K., Ishida, H., Hirasawa, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226707 · Cited by 31
Current methods in translational cancer research
Lee, M. W., Miljanic, M., Triplett, T., Ramírez, C., Aung, K. L., Eckhardt, S., & Capasso, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09931-5 · Cited by 32
Peng, P., Qiang, X., Li, G., Li, L., Ni, S., Yu, Q., Sourd, L., Marangoni, E., Hu, C., Wang, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0012 · Cited by 29
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
Styczen, H., Nagelmeier, I., Beißbarth, T., Nietert, M. M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3527 · Cited by 29
Tumor Heterogeneity and Personalized Cancer Medicine: Are we Being Outnumbered?
Cirkel, G. A., Hooijdonk, C. G. G., Koudijs, M. J., Willems, S. M., & Voest, E. E. (2014) · Future Oncology · doi:10.2217/fon.13.214 · Cited by 28
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, J., Li, S., Wang, B., Wu, Y., Chen, Z., Lv, M., Lin, Y., & Yang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5140-9 · Cited by 29
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 26
Selecting treatment options in refractory metastatic colorectal cancer
Byrne, M. M., & Saif, M. W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194605 · Cited by 28
Huang, W., Chen, Y., Chang, W., Ren, L., Tang, W., Zheng, P., Wu, Q., Liu, T., Liu, Y., Wei, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03655-x · Cited by 28
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28
Colorectal Cancer Stem Cells: An Overview of Evolving Methods and Concepts
Angelis, M. L. D., Francescangeli, F., Zeuner, A., & Baiocchi, M. (2021) · Cancers · doi:10.3390/cancers13235910 · Cited by 30
Prognostic Factors After Resection of Colorectal Liver Metastases: From Morphology to Biology
Ribero, D., Viganò, L., Amisano, M. F., & Capussotti, L. (2012) · Future Oncology · doi:10.2217/fon.12.159 · Cited by 28
Self-citationLuraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 28
Self-citationRituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
Corso, S., Cargnelutti, M., Durando, S., Menegon, S., Apicella, M., Migliore, C., Capelôa, T., Ughetto, S., Isella, C., Médico, E., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.003 · Cited by 28
Self-citationJacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 28
Shimada, Y., Kameyama, H., Nagahashi, M., Ichikawa, H., Muneoka, Y., Yagi, R., Tajima, Y., Okamura, T., Nakano, M., Sakata, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20510 · Cited by 27
Williams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X.-M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0120 · Cited by 26
Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 29
Zeng, M., Ruan, Z., Tang, J., Liu, M., Hu, C., Fan, P., & Dai, X. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02953-3 · Cited by 27
Claus, J., Patel, G. S., Ng, T., & Parker, P. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140043 · Cited by 26
Parikh, A. R., Atreya, C. E., Korn, W. M., & Venook, A. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0002 · Cited by 27
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 28
Self-citationHER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 28
Conradi, L., Spitzner, M., Metzger, A.-L. C., Kisly, M., Middel, P., Bohnenberger, H., Gaedcke, J., Ghadimi, M. B., Liersch, T., Rüschoff, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6051-0 · Cited by 27
Serum and tissue markers in colorectal cancer: State of art
Berretta, M., Alessandrini, L., Divitiis, C. D., Nasti, G., Lleshi, A., Francia, R. D., Facchini, G., Cavaliere, C., Buonerba, C., & Canzonieri, V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.007 · Cited by 28
Stewart, P., Richman, S. D., Maughan, T., Lawler, M., Dunne, P. D., & Salto‐Tellez, M. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.005 · Cited by 24
Maeda, T., Kitamura, S., Nishihara, H., & Yanagi, T. (2020) · Oncogene · doi:10.1038/s41388-020-01404-x · Cited by 27
Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
Tanaka, T., Nishie, R., Ueda, S., Miyamoto, S., Hashida, S., Konishi, H., Terada, S., Kogata, Y., Sasaki, H., Tsunetoh, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179369 · Cited by 25
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy DevelopmentPreprint
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Singh, H., Kang, A., Bloudek, L. M., Hsu, L., Palanca-Wessels, M. C., Stecher, M., Siadak, M. F., & Ng, K. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad082 · Cited by 27
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 28
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 29
Self-citationEmerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 26
The HER family as therapeutic targets in colorectal cancer
Ye, P., Wang, Y., Li, R., Chen, W., Wan, L., & Cai, P. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103681 · Cited by 27
Serra-Camprubí, Q., Verdaguer, H., Oliveros, W., Lupión-Garcia, N., Llop‐Guevara, A., Molina, C., Vila-Casadesús, M., Turpin, A., Neuzillet, C., Frigola, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2551 · Cited by 26
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 30
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Lam, M., Lum, C., Latham, S., Smith, S. T., Prenen, H., & Segelov, E. (2020) · Cancer Management and Research · doi:10.2147/cmar.s213236 · Cited by 26
Systems Biology and Experimental Model Systems of Cancer
Yalçın, G. D., Danisik, N., Baygin, R. C., & Acar, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040180 · Cited by 24
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Corso, S., Pietrantonio, F., Apicella, M., Migliore, C., Conticelli, D., Petrelli, A., D’Errico, L., Durando, S., Moya‐Rull, D., Bellomo, S. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0121 · Cited by 24
Self-citationPicco, G., Petti, C., Sassi, F. P., Grillone, K., Migliardi, G., Rossi, T., Isella, C., Nicolantonio, F. D., Sarotto, I., Sapino, A., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw209 · Cited by 24
Self-citationCurrent Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 25
Self-citationBrijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 23
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Petrelli, A., Rizzolio, S., Pietrantonio, F., Bellomo, S. E., Benelli, M., Cecco, L. D., Romagnoli, D., Berrino, E., Orrù, C., Ribisi, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2620 · Cited by 25
Self-citationPilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection
Mattos‐Arruda, L. D., & Rodon, J. A. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0135 · Cited by 23
Patient-derived tumor xenograft models for melanoma drug discovery
Harris, A. L., Joseph, R. W., & Copland, J. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1216968 · Cited by 23
Cleary, J. M., McRee, A. J., Shapiro, G. I., Tolaney, S. M., O’Neil, B. H., Kearns, J. D., Mathews, S., Nering, R., MacBeath, G., Czibere, A. G., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0399-7 · Cited by 22
A novel patient-derived xenograft model for claudin-low triple-negative breast cancer
Matossian, M. D., Burks, H. E., Bowles, A. C., Elliott, S. G., Hoang, V. T., Sabol, R. A., Pashos, N. C., O’Donnell, B. T., Miller, K. S., Wahba, B., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4685-2 · Cited by 23
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 22
The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms
Sievers, C. K., Kratz, J. D., Zurbriggen, L. D., LoConte, N. K., Lubner, S. J., Uboha, N., Mulkerin, D. L., Matkowskyj, K. A., & Deming, D. A. (2016) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0036-1584292 · Cited by 22
Li, Q., Dai, W., Liu, J., Li, Y., & Li, Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1785-7 · Cited by 23
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Morris, V. K., & Strickler, J. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-120448 · Cited by 23
Personalized therapeutic strategies in HER2-driven gastric cancer
Ughetto, S., Migliore, C., Pietrantonio, F., Apicella, M., Petrelli, A., D’Errico, L., Durando, S., Moya‐Rull, D., Bellomo, S. E., Rizzolio, S., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01165-w · Cited by 21
Self-citationRos, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 22
Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies
Kitsel, Y., Cooke, T., Sotirchos, V. S., & Sofocleous, C. T. (2023) · Cancers · doi:10.3390/cancers15061679 · Cited by 24
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 22
Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 22
Cheung, P. F., Yip, C. W., Ng, L. W. C., Lo, K. W., Chow, C., Chan, K. F., Cheung, T. T., & Cheung, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0322-5 · Cited by 22
Skowron, K. B., Pitroda, S. P., Namm, J. P., Balogun, O., Beckett, M. A., Zenner, M. L., Fayanju, O. M., Huang, X., Fernandez, C., Zheng, W., et al. (2016) · Scientific Reports · doi:10.1038/srep35854 · Cited by 22
Baraniskin, A., Laethem, J. V., Wyrwicz, L. S., Güller, U., Wasan, H. S., Matysiak‐Budnik, T., Gruenberger, T., Ducreux, M. P., Carneiro, F., Cutsem, E. V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.021 · Cited by 23
Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 22
Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology
Curran, M., Mairesse, M., Matas‐Céspedes, A., Bareham, B. R., Pellegrini, G., Liaunardy, A., Powell, E., Sargeant, R., Cuomo, E. M., Stebbings, R., et al. (2019) · Toxicologic Pathology · doi:10.1177/0192623319886304 · Cited by 23
Sheppard, H., Vogel, P., Rogers, T. D., Akers, W. J., & Rehg, J. E. (2020) · Veterinary Pathology · doi:10.1177/0300985820913265 · Cited by 22
Bagby, S. M., Messersmith, W. A., Pitts, T. M., Capasso, A., Varella-Garcia, M., Klauck, P. J., Kim, J., Tan, A. C., Eckhardt, S. G., Tentler, J. J., et al. (2016) · Journal of Visualized Experiments · doi:10.3791/54393 · Cited by 25
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Personalized treatment for advanced colorectal cancer: KRAS and beyond
Karapetis, C. S., & Patel, G. S. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35025 · Cited by 20
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 21
Performance of capecitabine in novel combination therapies in colorectal cancer
Pouya, F. D., Rasmi, Y., Camcı, İ. Y., Tutar, Y., & Nemati, M. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1920247 · Cited by 21
Kim, H., Kim, S. Y., Kim, J., Kim, J. E., Hong, Y. S., Han, B., Tak, E., Ryu, Y., Kim, S., & Kim, T. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-05694-x · Cited by 22
Patient‐derived xenograft model in colorectal cancer basic and translational research
Liu, X., Xin, Z., & Wang, K. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12299 · Cited by 22
Cascianelli, S., Barbera, C., Ulla, A. A., Grassi, E., Lupo, B., Pasini, D., Bertotti, A., Trusolino, L., Médico, E., Isella, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01176-5 · Cited by 20
Self-citationCiardiello, D., Mauri, G., Bianchi, A. S., Siena, S., Zampino, M. G., Fazio, N., & Cervantes, A. M. R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102683 · Cited by 23
Self-citationLenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
Leuci, V., Maione, F., Rotolo, R., Giraudo, E., Sassi, F. P., Migliardi, G., Todorovic, M., Gammaitoni, L., Mesiano, G., Giraudo, L., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0872-2 · Cited by 21
Self-citationHuman Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer
Bianchi, A. S., Marsoni, S., & Siena, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3323 · Cited by 21
Self-citationMazzeschi, M., Sgarzi, M., Romaniello, D., Gelfo, V., Cavallo, C., Ambrosi, F., Morselli, A., Miano, C., Laprovitera, N., Girone, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02309-1 · Cited by 21
Cytohesins/ARNO: The Function in Colorectal Cancer Cells
Pan, T., Sun, J., Hu, J., Hu, Y., Zhou, J., Chen, Z., Xu, D., Xu, W., Zheng, S. S., & Zhang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090997 · Cited by 21
Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 20
Self-citationMolecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 20
HER2 targeted therapy in colorectal Cancer: Current landscape and future directions
Chen, N., He, L. T., Zou, Q., & Deng, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116101 · Cited by 22
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
